Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
John P. Franklin, Mimoun Azzouz & Pamela J. Shaw. (2020) SOD1-targeting therapies for neurodegenerative diseases: a review of current findings and future potential. Expert Opinion on Orphan Drugs 8:10, pages 379-392.
Read now
Read now
Articles from other publishers (18)
Lijiang ShenAndrea WongSatoru OnedaBrian R. CurtisJoe SchroederTom Zanardi, Jeffery A. EngelhardtScott P. HenryPadmakumar Narayanan. (2023) Complement C3d/C4d Deposition on Platelets Correlates with 2′-O-Methoxyethyl Antisense Oligonucleotide-Induced Thrombocytopenia in Monkeys. Nucleic Acid Therapeutics 33:3, pages 209-225.
Crossref
Crossref
Adam J. PollakPatrick CauntayTodd MachemerSuzanne Paz, Sagar DamleScott P. HenrySebastien A. Burel. (2022) Inflammatory Non-CpG Antisense Oligonucleotides Are Signaling Through TLR9 in Human Burkitt Lymphoma B Bjab Cells. Nucleic Acid Therapeutics 32:6, pages 473-485.
Crossref
Crossref
Sebastien A. BurelTodd MachemerBrenda F. BakerT. Jesse KwohSuzanne Paz, Husam YounisScott P. Henry. (2022) Early-Stage Identification and Avoidance of Antisense Oligonucleotides Causing Species-Specific Inflammatory Responses in Human Volunteer Peripheral Blood Mononuclear Cells. Nucleic Acid Therapeutics 32:6, pages 457-472.
Crossref
Crossref
Benjamin D. Boros, Kathleen M. Schoch, Collin J. Kreple & Timothy M. Miller. (2022) Antisense Oligonucleotides for the Study and Treatment of ALS. Neurotherapeutics 19:4, pages 1145-1158.
Crossref
Crossref
Caitlyn L. Miller, Idit Sagiv-Barfi, Patrick Neuhöfer, Debra K. Czerwinski, Steven E. Artandi, Carolyn R. Bertozzi, Ronald Levy & Jennifer R. Cochran. (2022) Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression. Cell Chemical Biology 29:3, pages 451-462.e8.
Crossref
Crossref
Epaminondas Doxakis. (2020) Therapeutic antisense oligonucleotides for movement disorders. Medicinal Research Reviews 41:5, pages 2656-2688.
Crossref
Crossref
Suzan M Hammond, Annemieke Aartsma‐Rus, Sandra Alves, Sven E Borgos, Ronald A M Buijsen, Rob W J Collin, Giuseppina Covello, Michela A Denti, Lourdes R Desviat, Lucía Echevarría, Camilla Foged, Gisela Gaina, Alejandro Garanto, Aurelie T Goyenvalle, Magdalena Guzowska, Irina Holodnuka, David R Jones, Sabine Krause, Taavi Lehto, Marisol Montolio, Willeke Van Roon‐Mom & Virginia Arechavala‐Gomeza. (2021) Delivery of oligonucleotide‐based therapeutics: challenges and opportunities. EMBO Molecular Medicine 13:4.
Crossref
Crossref
Elaine PiriePatrick CauntayWuxia FuShayoni RayCalvin PanAldonis J. LusisJill HsiaoSebastien A. BurelPadma NarayananRosanne M. CrookeRichard G. Lee. (2019)
Hybrid Mouse Diversity Panel Identifies Genetic Architecture Associated with the Acute Antisense Oligonucleotide-Mediated Inflammatory Response to a 2′-
O
-Methoxyethyl Antisense Oligonucleotide
. Nucleic Acid Therapeutics 29:5, pages 266-277.
Crossref
Crossref
Padmakumar Narayanan, Lijiang Shen, Brian R Curtis, Mario A Bourdon, John P Nolan, Shipra Gupta, Christine Hoffmaster, Fangli Zhou, Bryan Christian, Jayne L Schaubhut, Sarah Greenlee, Sebastien A Burel, Joe L Witztum, Jeffrey A Engelhardt & Scott P Henry. (2018) Investigation into the Mechanism(s) That Leads to Platelet Decreases in Cynomolgus Monkeys During Administration of ISIS 104838, a 2ʹ-MOE-Modified Antisense Oligonucleotide. Toxicological Sciences 164:2, pages 613-626.
Crossref
Crossref
Thomas A. ZanardiTae-Won KimLijiang ShenDavid SerotaChris PapagiannisShin-Young ParkYunlip KimScott P. Henry. (2018)
Chronic Toxicity Assessment of 2′-
O
-Methoxyethyl Antisense Oligonucleotides in Mice
. Nucleic Acid Therapeutics 28:4, pages 233-241.
Crossref
Crossref
Rosanne Seguin. 2018. Oligonucleotide-Based Drugs and Therapeutics. Oligonucleotide-Based Drugs and Therapeutics
227
242
.
Suzanne PazJill HsiaoPatrick CauntayArmand SorianoLawrence BaiTodd MachemerXiaokun XiaoShuling GuoGene HungHusam YounisC. Frank BennettScott HenryTheodore J. YunSébastien Burel. (2017)
The Distinct and Cooperative Roles of Toll-Like Receptor 9 and Receptor for Advanced Glycation End Products in Modulating
In Vivo
Inflammatory Responses to Select CpG and Non-CpG Oligonucleotides
. Nucleic Acid Therapeutics 27:5, pages 272-284.
Crossref
Crossref
Scott P. HenryPadmakumar NarayananLijiang ShenSanjay BhanotHusam S. YounisSebastien A. Burel. (2017) Assessment of the Effects of 2′-Methoxyethyl Antisense Oligonucleotides on Platelet Count in Cynomolgus Nonhuman Primates. Nucleic Acid Therapeutics 27:4, pages 197-208.
Crossref
Crossref
Kathleen M. Schoch & Timothy M. Miller. (2017) Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases. Neuron 94:6, pages 1056-1070.
Crossref
Crossref
Sebastien A. Burel, Todd Machemer, Frank L. Ragone, Hiroki Kato, Patrick Cauntay, Sarah Greenlee, Aneeza Salim, William A. Gaarde, Gene Hung, Raechel Peralta, Susan M. Freier & Scott P. Henry. (2012)
Unique
O
-Methoxyethyl Ribose-DNA Chimeric Oligonucleotide Induces an Atypical Melanoma Differentiation-Associated Gene 5-Dependent Induction of Type I Interferon Response
. Journal of Pharmacology and Experimental Therapeutics 342:1, pages 150-162.
Crossref
Crossref
Anne Schlegel, Cyril Buhler, Flavien Devun, Céline Agrario, Saïk Urien, François Lokiec, Jian-Sheng Sun & Marie Dutreix. (2012) Pharmacokinetics and Toxicity in Rats and Monkeys of coDbait: A Therapeutic Double-stranded DNA Oligonucleotide Conjugated to Cholesterol. Molecular Therapy - Nucleic Acids 1, pages e33.
Crossref
Crossref
Wei Zou, Robert A. Roth, Husam S. Younis, Lyle D. Burgoon & Patricia E. Ganey. (2010) Oxidative stress is important in the pathogenesis of liver injury induced by sulindac and lipopolysaccharide cotreatment. Toxicology 272:1-3, pages 32-38.
Crossref
Crossref
Yanal M. Murad & Timothy M. Clay. (2009) CpG Oligodeoxyneucleotides as TLR9 Agonists. BioDrugs 23:6, pages 361-375.
Crossref
Crossref